Company Information
Company Profile
Avalo (AVTX) is a clinical stage biotechnology company focused on the treatment of immune mediated inflammatory diseases. Avalo’s lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases.
Latest Presentations
June 2025 Corporate Presentation
View This Presentation
Contact Information
Investor Relations
Avalo Therapeutics
ir@avalotx.com